Ridaforolimus

Search with Google Search with Bing

Information
Drug Name
Ridaforolimus
Description
Entry(CIViC)
3
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
endometrial cancer PIK3CA MUTATION PIK3CA MUTATION B Predictive Does Not Support Sensitivity/Response Somatic 3 24166148 Detail
endometrial cancer PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		B Predictive Does Not Support Resistance Somatic 3 24166148 Detail
endometrial cancer KRAS MUTATION KRAS MUTATION B Predictive Does Not Support Sensitivity/Response Somatic 2 24166148 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
94 endometrial cancer samples of women who had bee... PIK3CA PIK3CA MUTATION PIK3CA MUTATION Sensitivity false CIViC Evidence detail
94 endometrial cancer samples of women who had bee... PTEN PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		Resitance or Non-Reponse false CIViC Evidence detail
94 endometrial cancer samples of women who had bee... KRAS KRAS MUTATION KRAS MUTATION Sensitivity false CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT01605396 Completed Phase 2 A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) July 4, 2012 March 15, 2018
NCT00060645 Completed Phase 1 Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) May 2003 February 2009
NCT00086125 Completed Phase 2 Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) June 2004 June 2006
NCT00093080 Completed Phase 2 Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) October 2004 November 2008
NCT00110188 Completed Phase 2 Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) May 2005 August 2007
NCT00112372 Completed Phase 1 Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) May 2005 March 2009
NCT00122343 Completed Phase 2 AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) August 2005 January 2008
NCT00288431 Completed Phase 1 Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) February 2006 July 2008
NCT00538239 Completed Phase 3 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) October 2007 December 2012
NCT00694083 Completed Phase 1 Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) June 10, 2008 September 6, 2009
NCT00704054 Completed Phase 1 A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED) January 2008 June 2010
NCT00736970 Completed Phase 2 Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) July 2008 May 2011
NCT00739830 Completed Phase 2 Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) August 2008 July 2012
NCT00770185 Completed Phase 2 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer November 13, 2008 February 13, 2015
NCT00781846 Completed Phase 1 Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) October 2008 February 2010
NCT01010672 Completed Phase 2 Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) November 2009 January 2013
NCT01043887 Completed Phase 1 Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046) January 2010 April 2010
NCT01071304 Completed Phase 1 Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044) March 2010 February 2012
NCT01169532 Completed Phase 1 Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma October 2010 March 2014
NCT01295632 Completed Phase 1 Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) February 2011 August 2015
NCT01380184 Completed Phase 1 Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) July 5, 2011 April 5, 2012
NCT01431547 Completed Phase 1 Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) February 2012 September 2013
NCT00060632 Completed Phase 1 Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) April 2003 October 2005
NCT01220570 Completed Phase 1 The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) September 2010 December 2012
NCT01234857 Completed Phase 2 A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) September 17, 2010 October 15, 2013
NCT01256268 Completed Phase 1 Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids June 13, 2011 August 3, 2017
NCT01212627 Terminated Phase 1 Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer September 2010 April 2013
NCT01431534 Terminated Phase 1 A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) January 30, 2012 May 25, 2018
NCT01243762 Terminated Phase 1 A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) November 22, 2010 March 25, 2013
NCT01296659 Withdrawn Phase 1 Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma February 2011 August 2011